Inari Medical (NARI) Stock Price, News & Analysis

Company Overview

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $52.64 to $56.11
• 50-Day Range: $42.20 to $58.21
• 52-Week Range: $36.73 to $66.61
• Volume: 828,590 shs
• Average Volume: 998,227 shs
• Market Capitalization: $3.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $61.80
• Consensus Rating: Moderate Buy

Inari Medical Stock Analysis - MarketRank™

Inari Medical scored higher than 67% of companies evaluated by MarketBeat, and ranked 341st out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inari Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Inari Medical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inari Medical are expected to grow in the coming year, from ($0.77) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inari Medical is -39.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inari Medical is -39.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inari Medical has a P/B Ratio of 6.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.99% of the outstanding shares of Inari Medical have been sold short.

Short Interest Ratio / Days to Cover

Inari Medical has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inari Medical has recently decreased by 14.62%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inari Medical does not currently pay a dividend.

Dividend Growth

Inari Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.99% of the outstanding shares of Inari Medical have been sold short.

Short Interest Ratio / Days to Cover

Inari Medical has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inari Medical has recently decreased by 14.62%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.49

News Sentiment

Inari Medical has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Inari Medical this week, compared to 10 articles on an average week.

Search Interest

Only 1 people have searched for NARI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Inari Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Inari Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,527,870.00 in company stock.

Percentage Held by Insiders

10.60% of the stock of Inari Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.98% of the stock of Inari Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NARI Stock Analysis - Frequently Asked Questions

How have NARI shares performed this year?

Inari Medical's stock was trading at $64.92 at the beginning of 2024. Since then, NARI stock has decreased by 18.1% and is now trading at $53.19.
View the best growth stocks for 2024 here.

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.01 by $0.09. The company's revenue for the quarter was up 22.5% compared to the same quarter last year.

When did Inari Medical IPO?

Inari Medical (NARI) raised $110 million in an initial public offering on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Who are Inari Medical's major shareholders?

Top institutional shareholders of Inari Medical include State Street Corp (3.48%), Jennison Associates LLC (2.69%), Vestal Point Capital LP (2.65%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.17%). Insiders that own company stock include Donald B Milder, William Hoffman, Andrew Hykes, Thomas Tu, Mitch C Hill and Rebecca Chambers.
View institutional ownership trends.

How do I buy shares of Inari Medical?

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inari Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 2/28/2024
• Today: 12/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NARI
• CUSIP: N/A
• CIK: 1531048
• Web: www.inarimedical.com
• Phone: 877-923-4747
• Fax: N/A
• Employees: 1,300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $61.80
• High Stock Price Target: $75.00
• Low Stock Price Target: $47.00
• Potential Upside/Downside: +16.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,640,000.00
• Net Margins: -13.68%
• Pretax Margin: -9.29%
• Return on Equity: -10.09%
• Return on Assets: -6.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.77
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $574.50 million
• Price / Sales: 5.43
• Cash Flow: $0.08 per share
• Price / Cash Flow: 630.46
• Book Value: $8.07 per share
• Price / Book: 6.60

Miscellaneous

• Outstanding Shares: 58,544,000
• Free Float: 52,338,000
• Market Cap: $3.12 billion
• Optionable: Optionable
• Beta: 0.97